{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:07:23Z","timestamp":1747181243496,"version":"3.40.5"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,15]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Medical therapy has become an increasingly important intervention owing to improvements in the multidisciplinary care for pituitary adenomas (PAs). This study aimed to assess the reporting quality of randomized controlled trials (RCTs) on PAs pharmacotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>RCTs evaluating the efficacy of pharmacotherapy in PAs published in English between January 1, 1974, and December 31, 2022, were searched for and collected from PubMed and MEDLINE. The 2010 Consolidated Standards for Test Reports (CONSORT) statement-based 28 items overall quality score (OQS) was used to evaluate the overall quality of each report.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Twenty-seven related RCTs including 1816 patients were retrieved. The median OQS score was 12 (range, 6\u201319) on a scale of 0 to 28. Important items, such as background, objectives, participants, interventions, and outcomes, were sufficiently reported in 100% (27\/27) of the articles. Statistical methods were adequately described in 93% (25\/27) of patients. However, RCTs underreported identification as randomized trials in the title (3\/27, 11%), sample size, allocation concealment, implementation, ancillary analysis method, and Diagram and Ancillary analyses (1\/27, 4%). The OQS of published RCTs has significantly increased since 2010 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.012). The multivariate final model showed significant associations between higher OQS and publication since 2010 and enrollment of more than 100 patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The overall reporting quality of RCTs on pharmacotherapy in PAs was poor, based on the 2010 CONSORT statement. However, we noticed an improvement in the OQS over the years and identified the factors associated with a better report. Increased effort is necessary to raise awareness of these issues among writers, readers, reviewers, and editors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000037518","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T21:04:35Z","timestamp":1710536675000},"page":"e37518","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The reporting quality of randomized controlled trials in pharmacotherapy for pituitary adenomas"],"prefix":"10.1097","volume":"103","author":[{"given":"Hongmei","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Weifang People\u2019s Hospital, Weifang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiyan","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Clinical Medical School of Shangdong University, Jinan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Weifang People\u2019s Hospital, Weifang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Weifang People\u2019s Hospital, Weifang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6411-9842","authenticated-orcid":false,"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Weifang People\u2019s Hospital, Weifang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine.","volume":"128","author":"Burns","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.","volume":"23340","author":"Moher","year":"2010","journal-title":"BMJ"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archderm.136.3.381","article-title":"How well are randomized controlled trials reported in the dermatology literature?","volume":"136","author":"Adetugbo","year":"2000","journal-title":"Arch Dermatol"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1001\/jama.285.15.2006","article-title":"CONSORT revised-improving the reporting of randomized trials.","volume":"285","author":"Rennie","year":"2001","journal-title":"JAMA"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fendo.2020.00054","article-title":"Experimental evidence and clinical implications of pituitary adenoma stem cells.","volume":"11","author":"W\u00fcrth","year":"2020","journal-title":"Front Endocrinol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"101309","DOI":"10.1016\/j.beem.2019.101309","article-title":"The burden of disease for pituitary patients.","volume":"33","author":"Biermasz","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical biology of the pituitary adenoma.","volume":"43","author":"Melmed","year":"2022","journal-title":"Endocr Rev"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"868174","DOI":"10.3389\/fendo.2022.868174","article-title":"Editorial: refractory pituitary adenoma-current challenges and emerging treatments.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"1060884","DOI":"10.3389\/fendo.2022.1060884","article-title":"Individualized medical treatment options in Cushing disease.","volume":"13","author":"Gilis-Januszewska","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000521388","article-title":"The involvement of miRNAs in pituitary adenomas pathogenesis and the clinical implications.","volume":"85","author":"Xu","year":"2022","journal-title":"Eur Neurol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.21037\/gs-20-873","article-title":"Diagnosis and treatment of refractory pituitary adenomas: a narrative review.","volume":"10","author":"Liu","year":"2021","journal-title":"Gland Surg"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"101713","DOI":"10.1016\/j.beem.2022.101713","article-title":"Temozolomide in aggressive pituitary tumours and pituitary carcinomas.","volume":"36","author":"McCormack","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11102-020-01040-4","article-title":"Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.","volume":"23","author":"Lizzul","year":"2020","journal-title":"Pituitary"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fendo.2019.00358","article-title":"Editorial: targeted therapy for pituitary adenomas.","volume":"10","author":"Araki","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"773905","DOI":"10.3389\/fonc.2021.773905","article-title":"Anti-VEGF therapy in refractory pituitary adenomas and pituitary carcinomas: a review.","volume":"11","author":"Dai","year":"2021","journal-title":"Front Oncol"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12957-021-02272-9","article-title":"Research advances on the immune research and prospect of immunotherapy in pituitary adenomas.","volume":"19","author":"Nie","year":"2021","journal-title":"World J Surg Oncol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2005.03.1179","article-title":"Quality of randomized controlled trials reporting in the primary treatment of brain tumors.","volume":"24","author":"Lai","year":"2006","journal-title":"J Clin Oncol"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1371\/journal.pmed.0050020","article-title":"CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration.","volume":"5","author":"Hopewell","year":"2008","journal-title":"PLoS Med"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.msard.2016.07.013","article-title":"Reporting quality of randomized- controlled trials in multiple sclerosis from 2000 to 2015,based on CONSORT statement.","volume":"9","author":"Rikos","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1111\/1759-7714.14114","article-title":"Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer.","volume":"12","author":"Du","year":"2021","journal-title":"Thorac Cancer"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11239-020-02315-0","article-title":"Analysis of the quality of reporting of randomized controlled trials in anticoagulant versus antiplatelet medication for venous thromboembolism prophylaxis as governed by the CONSORT statement.","volume":"52","author":"Beneki","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"R23-20250503","first-page":"148","article-title":"Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients.","volume":"8","author":"Garnier","year":"2020","journal-title":"Neurooncol Pract"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1634\/theoncologist.2017-0196","article-title":"Quality of randomized controlled trials reporting in the treatment of adult patients with high-grade gliomas.","volume":"23","author":"Tardy","year":"2018","journal-title":"Oncologist"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1007\/s00345-020-03501-8","article-title":"The reporting quality of randomized controlled trials and experimental animal studies for urethroplasty.","volume":"39","author":"Albersheim","year":"2021","journal-title":"World J Urol"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"e1696","DOI":"10.1093\/cid\/ciaa1353","article-title":"Methodological and reporting quality of noninferiority randomized controlled trials comparing antibiotic therapies: a systematic review.","volume":"73","author":"Bai","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/cid\/ciad308","article-title":"Methodological and reporting quality of non-inferiority randomised controlled trials comparing antiretroviral therapies: a systematic review.","volume":"77","author":"Lo","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jama.295.10.1147","article-title":"Quality of reporting of noninferiority and equivalence randomized trials.","volume":"295","author":"Le Henanff","year":"2006","journal-title":"JAMA"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"e13550","DOI":"10.1371\/journal.pone.0013550","article-title":"Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review.","volume":"5","author":"Wangge","year":"2010","journal-title":"PLoS One"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"e012594","DOI":"10.1136\/bmjopen-2016-012594","article-title":"Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals.","volume":"6","author":"Rehal","year":"2016","journal-title":"BMJ Open"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijrobp.2017.01.214","article-title":"Reporting quality of randomized, controlled trials evaluating combined chemoradiotherapy in nasopharyngeal carcinoma.","volume":"98","author":"Chen","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:05:12Z","timestamp":1746317112000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037518","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,3,15]]}}}